Reduced antithrombin III levels during L-asparaginase therapy

Area of Science:

• Biochemistry
• Hematology
• Pediatric Oncology

Background:

• Acute lymphoblastic leukemia (ALL) is a common childhood cancer.
• L-asparaginase is a key chemotherapeutic agent used in ALL treatment.
• Antithrombin III (AT-III) is a crucial protein involved in blood coagulation.

Purpose of the Study:

• To investigate the effect of different L-asparaginase dosage regimens on Antithrombin III levels in children with ALL.
• To explore the potential mechanism behind observed changes in AT-III levels.

Main Methods:

• Serum samples were collected from 11 children with ALL before, during, and after L-asparaginase therapy.
• Antithrombin III levels were measured using both functional and immunologic assays.
• Therapy involved three distinct dosage regimens: daily, alternate-day, and every 10 days.

Main Results:

• Transient reductions in Antithrombin III levels were observed during daily and alternate-day L-asparaginase treatment.
• Antithrombin III levels remained unaffected when L-asparaginase was administered every 10 days.
• The findings suggest impaired hepatic synthesis of AT-III.

Conclusions:

• The dosage and frequency of L-asparaginase administration significantly impact Antithrombin III levels in pediatric ALL patients.
• Less frequent L-asparaginase dosing (every 10 days) may mitigate the risk of AT-III deficiency.
• Impaired hepatic synthesis is the likely mechanism for L-asparaginase-induced AT-III reduction.